• 1. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines N-alkylpiperazines

Introduction to 1-(2-methylbutyl)piperazine (CAS No. 82499-91-0)

1-(2-methylbutyl)piperazine, identified by the Chemical Abstracts Service Number (CAS No.) 82499-91-0, is a significant compound in the field of pharmaceutical chemistry and drug development. This piperazine derivative has garnered attention due to its structural properties and potential applications in medicinal chemistry. Piperazine derivatives are well-known for their role as intermediates in the synthesis of various bioactive molecules, including drugs targeting neurological and cardiovascular disorders.

The molecular structure of 1-(2-methylbutyl)piperazine consists of a piperazine ring substituted with a 2-methylbutyl group. This substitution pattern imparts unique physicochemical properties, such as solubility and metabolic stability, which are critical factors in drug design. The compound's ability to interact with biological targets makes it a valuable scaffold for developing novel therapeutic agents.

In recent years, there has been growing interest in exploring the pharmacological potential of 1-(2-methylbutyl)piperazine. Research studies have highlighted its role as a precursor in the synthesis of compounds with potential applications in treating conditions such as hypertension and anxiety disorders. The piperazine moiety is known to exhibit dopaminergic and serotonergic activity, which has been leveraged in the development of drugs for neurological disorders.

One of the most compelling aspects of 1-(2-methylbutyl)piperazine is its versatility in drug design. Chemists have utilized this compound as a building block to create more complex molecules with enhanced pharmacological profiles. For instance, derivatives of 1-(2-methylbutyl)piperazine have been investigated for their potential as antihypertensive agents, owing to their ability to modulate vascular tone and neurotransmitter release.

The synthesis of 1-(2-methylbutyl)piperazine typically involves multi-step organic reactions, starting from readily available precursors. The process often includes functional group transformations such as alkylation and reduction, which are well-established in synthetic organic chemistry. The efficiency and scalability of these synthetic routes are crucial for industrial applications, where large quantities of the compound may be required for preclinical and clinical studies.

From a pharmacological perspective, 1-(2-methylbutyl)piperazine has shown promise in preclinical models as a potential treatment for various diseases. Its ability to cross the blood-brain barrier makes it an attractive candidate for central nervous system (CNS) drugs. Additionally, its structural similarity to known pharmacophores suggests that it may exhibit similar biological activities while offering new therapeutic options.

Recent advancements in computational chemistry have further enhanced the understanding of 1-(2-methylbutyl)piperazine's interactions with biological targets. Molecular modeling studies have helped identify key binding sites on proteins relevant to neurological disorders, providing insights into how this compound may modulate disease pathways. These findings are particularly valuable for designing next-generation drugs with improved efficacy and reduced side effects.

The pharmaceutical industry continues to invest in research related to 1-(2-methylbutyl)piperazine, recognizing its potential as a lead compound or intermediate in drug development. Collaborative efforts between academic researchers and industry scientists have led to innovative approaches in synthesizing and optimizing derivatives of this compound. Such collaborations are essential for translating laboratory discoveries into viable therapeutic solutions.

Regulatory considerations play a significant role in the development and commercialization of compounds like 1-(2-methylbutyl)piperazine. Compliance with Good Manufacturing Practices (GMP) and other regulatory guidelines ensures that pharmaceutical products derived from this compound meet stringent quality standards. Regulatory agencies also require comprehensive toxicological data to assess the safety profile of new drugs before they can be approved for clinical use.

The future prospects of 1-(2-methylbutyl)piperazine appear promising, with ongoing research exploring its applications in diverse therapeutic areas. Innovations in drug delivery systems and combination therapies may further enhance the therapeutic potential of this compound. As our understanding of disease mechanisms evolves, so too will the ways in which we utilize compounds like 1-(2-methylbutyl)piperazine to address unmet medical needs.

• 34581-23-2(1-(3-methylbutyl)piperazine)
• 82534-54-1(1-(Cyclobutylmethyl)piperazine)
• 57184-23-3(1-(Cyclohexylmethyl)piperazine)
• 57184-25-5(1-(Cyclopropylmethyl)piperazine)
• 1015846-52-2((1-((4-Methylpiperazin-1-yl)methyl)cyclopropyl)methanamine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)